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Human Langerhans Cells Are More Efficient Than
CD14CD1cþ Dermal Dendritic Cells at Priming
Naive CD4þ T Cells
Laetitia Furio1, Isabelle Briotet1, Alexandra Journeaux1, Hermine Billard1 and Josette Pe´guet-Navarro1
Few data are available regarding the role of human skin dendritic cells (DCs) in driving T-cell responses. In this
study we analyzed the relative capacity of Langerhans cells (LCs) and dermal CD14CD1cþ DCs (DDCs) to
trigger naive CD4þ T-cell proliferation and differentiation. DC subsets were purified after a 2-day migration
from epidermis and dermis of the same skin sample. Migratory LCs showed far more activated phenotype than
CD1cþDDCs and distinct expression of new molecules of the B7 family; when compared with LCs, CD1cþDDCs
showed higher PD-L1 and lower inducible co-stimulator ligand (ICOS-L) expression. As expected, CD1cþDDCs
showed lower allostimulatory property than LCs, a process that was partly reversed by anti-PD-L1 mAb. LCs
were significantly more efficient than CD1cþDDCs at inducing allogeneic naive CD4þ T cells to secrete both
T helper cell 1 (Th1; IFN-g and tumor necrosis factor-a ) and Th2 (IL-4 and IL-5) cytokines. Moreover, anti-PD-L1
mAb increased the production of IFN-g by both LC- and CD1cþDDC-stimulated T cells. Globally, these results
argue for a preponderant role of human LCs in inducing naive CD4þ T-cell priming. Low expression of
co-stimulatory molecules together with high expression of PD-L1 might limit the efficiency of CD1cþDDCs
at inducing naive CD4þ T-cell proliferation and secretion of cytokines.
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INTRODUCTION
Dendritic cells (DCs) are specialized antigen-presenting
cells (APCs) with the unique ability to initiate primary T-cell
immune responses (Steinman, 1991; Banchereau et al., 2000;
Ueno et al., 2007). They belong to a heterogeneous family of
cells of hematopoietic origin and are found in all tissues,
including blood and lymphoid organs. DCs reside in an
immature stage in peripheral tissues. In response to danger
signals leading to the local production of pro-inflammatory
cytokines, DCs undergo a complex process of activation and
then migrate to draining lymph nodes, where they initiate
primary T-cell responses (Valladeau and Saeland, 2005;
Ueno et al., 2007). Specifically, DCs acquire or upregulate a
unique set of cell-surface protein ligands that bind to specific
receptors on lymphocytes and regulate naive T-cell activa-
tion. The well-known CD80 or CD86/CD28 interaction
promotes T-cell activation and immunity, whereas CD80 or
CD86 interaction with cytotoxic T-lymphocyte antigen 4
(CTLA-4) on the T cells provides an inhibitory signal.
Moreover, several newly characterized members of the B7
family, including inducible co-stimulator ligand (ICOS-L/
B7-H2/CD275), programmed death ligand-1 (PD-L1,
B7-H1/CD274), and PD-L2 (B7-DC/CD273), were recently
found to have critical roles in controlling immune responses
(Carreno and Collins, 2002; Greenwald et al., 2005; Fife and
Bluestone, 2008). Both PD-L1 and PD-L2 interact with the
PD-1 receptor on activated T cells and modulate TCR
signaling, thereby downregulating T-cell responses, whereas
most studies have depicted ICOS/ICOS-L interactions as
co-stimulatory signals.
Depending on many factors, including their activation/
maturation state, the antigen dose, and the cytokine environ-
ment, DCs control the polarization of immune T-cell
responses. Thus, the DC-provided signals can induce the
differentiation of CD4þ T cells into T helper cell 1 (Th1;
producing IL-2 and IFN-g), Th2 (IL-4, IL-5, and IL-13), Th17
(IL-17), or even regulatory T cells (Kapsenberg, 2003;
Trinchieri, 2003; Stockinger and Veldhoen, 2007).
The skin is a crucial barrier against the external environ-
ment, and any breach of it requires a vigorous immune
response. In human skin, distinct types of myeloid DCs are
found in the two distinct epidermal and dermal layers
(Valladeau and Saeland, 2005). The best-identified of these
DCs—the Langerhans cells (LCs)—are located in the basal
and supra-basal layers of the epidermis and represent 2–4% of
the total epidermal cell population. Besides expression of
CD1 and major histocompatibility complex class II molecules
that differentiate them from surrounding melanocytes and
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keratinocytes, LCs have the C-type lectin-specific marker
langerin, which is responsible for the formation of cytoplas-
mic Birbeck granules (Valladeau et al., 2000). Dermal
dendritic cells (DDCs), also called interstitial DCs, have
been less characterized, mainly because they lack specific
markers. They share several membrane antigens with resident
dermal macrophages, such as CD45 and major histocompat-
ibility complex class II molecules, and were first identified
via their allostimulatory property and expression of CD1
molecules at the cell surface (Nestle et al., 1993; Meunier
et al., 1993). Dermal CD1aþ cells localize close to lymphatic
vessels, are different from LCs, and, unlike CD14þ dermal
cells, migrate in response to CC chemokine receptor 7 ligand
(Angel et al., 2006). Recently, more detailed analyses of
human dermal APCs have revealed the presence of at least
two migratory CD1aþCD14 and CD1aþ / CD14þ DC
subsets (Klechevsky et al., 2008; Haniffa et al., 2009), in
addition to the resident CD163þCD14þCD1factor XIIIaþ
macrophage population (Zaba et al., 2007, Haniffa et al.,
2009). The relative capacity of human LCs and the DDC
subsets to trigger naive T-cell response and to regulate the
balance between immunity and peripheral tolerance has
been little studied. A recent study indicates functional
differences between epidermal and dermal DC populations
(Klechevsky et al., 2008). Specifically, migratory CD14þ
DDCs were shown to have the unique capacity to induce
naive B cells to switch isotype and produce large amounts
of Ig.
In this study, we focused on human LCs and CD14
CD1cþDDCs migrating from the same skin explants and
undertook a comparative characterization of cell phenotype
and function in standard assays of T-cell proliferation and
differentiation. Our results showed that human LCs were far
more efficient than CD14CD1cþDDC at inducing naive
CD4þ T cells to proliferate and produce Th1 and Th2
cytokines. Most interestingly, the lower efficiency of
CD1cþDDC to prime the T cells was related, at least partly,
to expression of PD-L1 that downregulates both naive CD4þ
T-cell proliferation and secretion of Th1 cytokines.
RESULTS
Migratory LCs show a more activated phenotype than
migratory CD14 CD1cþDDCs
We harvested the cells migrating spontaneously from the
epidermis and dermis of the same skin sample after a
2-day culture. The number of migratory DCs averaged
1.8106±1.7 106 per g of epidermis and 0.45106±
0.32106 per g of dermis (mean±SD from 13 experiments),
as assessed using conventional microscopy. Dermal DCs
were first depleted of CD14þ cells and then purified using
human anti-CD1c-coupled microbeads. Indeed, we and
others have shown that CD1a expression decreases on
migratory DDCs, whereas CD1c is maintained at the cell
surface (Furio et al., 2005; Zaba et al., 2007). The migratory
LCs were purified using either density centrifugation or, as for
DDCs, human anti-CD1c-coupled microbeads; both techni-
ques yielded similar phenotypic and functional results. After
purification, the DC yield, i.e., the absolute number of DCs
recovered after purification in relation to the absolute number
of migratory DCs, was approximately 50% (47±23% for LCs
and 47±19% for CD14DDCs, mean±SD from 13 experi-
ments). The purity of LC and DDC suspensions was routinely
490%, as assessed using double staining with anti-CD1c and
HLA-DR mAbs (Figure 1a). Note that some CD1cþDDCs were
CD1a and that the percentage of langerinþ and CD14þ DC
cells was o2% in the DDC suspension. Moreover, the
CD14CD1cþ DDCs did not express DC-SIGN (DC-specific
ICAM-grabbing nonintegrin). These results were representative
of 13 experiments carried out with different donors.
As illustrated in Figure 1b, both migratory LCs and
CD1cþDDC cells express the maturation marker DC-LAMP
(DC-lysosome-associated membrane protein). In contrast,
migratory LCs showed a far more activated phenotype than
CD1cþDDCs, as revealed by higher levels of CD40, CD54,
CD80, CD83, and CD86. The mean fluorescence intensity
(MFI) of the antigens was measured in six experiments and the
ratio, MFI on LC/MFI on DDC, was calculated (Table 1). The
results confirmed that in all experiments LCs expressed higher
levels of all the above-mentioned co-stimulatory molecules.
Interestingly, migratory LCs and CD1cþDDCs differently
expressed the molecules of the B7-H family, namely PD-L1
(B7-H1 and CD274) and ICOS-L (B7-H2, B7-RP1, and
CD275). When compared with LCs, CD1cþDDCs expressed
lower ICOS-L and higher PD-L1 levels at the cell surface.
Thus, in six experiments, the mean percentage of ICOS-L-
positive cells was 36±15 for CD1cþDDCs versus 60±13 for
LCs, whereas the mean percentage of PD-L1-positive cells
was 84±8 for CD1cþDDCs versus 56±8 for LCs. Moreover,
the ratio, MFI on LC/MFI on CD1cþDDC, averaged
0.7±0.15 for PD-L1 and 2.6±0.7 for ICOS-L (Figure 1b,
Table 1). Neither mature migratory LCs nor CD1cþDDCs
expressed substantial levels of PD-L2 (B7-DC and CD273,
Figure 1b).
We analyzed the cytokines produced by the skin DCs after
a 2-day culture incubation in the presence or absence of poly
(I:C), a synthetic mimetic of viral double-stranded DNA. LCs,
and especially CD1cþDDCs, secrete high amounts of IL-8
(8,003±1,640 and 23,489±4,711 pg ml–1, respectively,
mean of three experiments), which was slightly increased
by poly (I:C). In contrast, IL-1b, IL-6, or IL-10 and IL-12p70
were not found in detectable amounts in the supernatants
from unstimulated or stimulated skin DCs (not shown).
Similar results were obtained after skin DC stimulation with
CD40L-transfected fibroblasts and IFN-g (not shown).
Migratory LCs show higher allostimulatory capacity than
migratory CD1cþDDCs
DCs have the unique capacity to trigger allogeneic naive
T-cell proliferation, and their activation state has a key role
in this process. Therefore, we examined the efficiency of
migratory LCs and CD1cþDDCs at activating naive T-cell
proliferation. As shown in Figure 2, LCs were far more
efficient than CD1cþDDCs at triggering allogeneic naive
CD4þ T-cell proliferation. Similar results were obtained
using total T cells from peripheral blood (not shown).
Moreover, although the proliferation rate was lower, LCs
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were more powerful stimulators of allogeneic naive CD8þ
T-cell proliferation (Figure 2b).
Migratory LCs are more efficient than CD1cþDDCs at priming
naive CD4þ T cells to produce both Th1 and Th2 cytokines
We then analyzed the ability of LCs and CD1cþDDCs to
support allogeneic naive CD4þ T-cell differentiation. To this
end, naive CD4þ T cells were co-cultured with LCs or
CD1cþDDCs for 6 days at a 1:10 APC/T-cell ratio and re-
stimulated with polyclonal T-cell stimuli. Intracellular cyto-
kine staining (Figure 3a) showed that LCs induced a higher
frequency of IFN-g and especially IL-4-producing CD4þ
T cells, whereas CD1cþDDCs induced a higher frequency of
IL-10-producing CD4þT cells. Moreover, as illustrated by the
results of nine independent experiments (Figure 3b), LCs
induced higher production of the Th1 cytokines IFN-g and
tumor necrosis factor-a than CD1cþDDCs. LCs were also far
more efficient at inducing naive CD4þ T cells to produce
Th2 (IL-4 and IL-5) cytokines by the naive T cells. In line with
intracellular cytokine staining, naive CD4þ T cells secrete
higher levels of IL-10 when stimulated by CD1cþDDCs
when compared with LCs.
When the APC/T-cell ratio was decreased to 1:100, both
LC-induced IFN-g and IL-4 production were maintained
or even increased (Figure 3c), demonstrating the very strong
capacity of human LCs to prime naive CD4þ T cells. In
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Figure 1. Human migratory Langerhans cells (LCs) show a more activated phenotype than migratory CD1cþ dermal dendritic cells (DDCs). LCs and
CD1cþDDCs were purified after a 2-day migration from epidermis and dermis of the same skin sample and analyzed using flow cytometry. (a) Cells were
double-stained with the indicated mAbs to assess the purity of DC suspensions. Numbers represent the percentage of cells in the respective quadrants.
(b) Migrating LCs and DDCs were double-stained with anti-CD1c and the indicated mAbs. Flow cytometry profiles are from a representative experiment.
The left-hand histograms represent the results obtained with isotype-matched control antibodies. Numbers indicate the mean fluorescence intensity for each antigen.
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contrast, cytokine production by CD1cþDDC-stimulated
CD4þ T cells was reduced. Interestingly, however, at the
low APC/T-cell ratio, LCs were very efficient at inducing
IL-10 production by T cells (Figure 3c).
PD-L1 expression on CD1cþDDCs regulates the proliferation
and differentiation of naive CD4þ T cells
Recent data have suggested that new molecules of the B-7
family, including PD-L1 and ICOS-L, can regulate the T-cell
response. Therefore, we analyzed their role in driving
LC- and CD1cþDDC-induced naive CD4þ T-cell priming.
To this end, LCs and CD1cþDDCs were treated with specific
mAbs before being added to the T cells. CTLA-4/Ig fusion
protein that blocks both CD80 and CD86 was used as
control. As expected, and shown in Figure 4a, CTLA-4/Ig
(20 mg ml–1) almost completely blocks the allogeneic T-cell
response, thus showing the importance of CD80/CD86
signaling in the skin DC-induced naive T-cell proliferation.
DC treatment with anti-ICOS-L mAb (up to 50 mg ml–1) did not
alter the LC- or DDC-induced T-cell proliferation. Similarly,
anti-PD-L1 mAb had no effect when added to LCs, using
either a 1:10 (Figure 4) or 1:100 LC/T-cell ratio (not shown).
In sharp contrast, CD1cþDDC treatment with anti-PD-L1
mAb consistently increased their capacity to induce naive
CD4þ T cell proliferation. In four experiments, the count-
per-minute values were about three times higher in the
presence of the mAb (from 2.3 to 3.5 times).
We then analyzed whether PD-L1, ICOS-L, or CD80/86
blockade could regulate the cytokine profile of LC- or DDC-
stimulated naive CD4þ T cells. As shown in Figure 4b, CTLA-
4/Ig consistently decreased the production of all the tested
cytokines by LC- or CD1cþDDC-stimulated naive CD4þ
T cells. In contrast, at concentrations up to 50 mg ml–1, anti-
ICOS-L mAb had no significant effect. Interestingly, PD-L1
blockade decreased the production of IL-4 and increased the
production of IFN-g by LC-stimulated T cells. Moreover, it
increased IL-10 and, more significantly, IFN-g production by
CD1cþDDCs. Altogether, these results are in line with
involvement of PD-L1 in the proliferation and differentiation
of naive CD4þ T cells.
CD1cþDDCs retain high expression of PD-L1 when stimulated
with CD40L and IFN-c
In this in vitro model, migratory DDCs were exposed to a
dermal environment. Within the dermis, resident macro-
phages are known to produce IL-10 (Klechevsky et al., 2008),
and it might be that this cytokine or other dermis-derived
immunosuppressive factors had hampered the activation of
CD1cþDDCs during migration, thereby introducing a bias in
our results. To clarify this point, migratory LCs and
CD1cþDDCs were purified and further incubated for 2 days
in GM-CSF-supplemented medium. After incubation, the
Table 1. Migratory LCs and CD1c+DDCs display a distinct activation phenotypic profile
MFI on LC/MFI on CD1c+DDC
HLA-DR CD40 CD54 CD80 CD86 CD83 PD-L1 ICOS-L DC-LAMP
Exp. 1 2.8 2.3 ND 4.5 5.2 1.5 0.45 2.9 ND
Exp. 2 0.85 1.5 ND 4.8 3.4 1.1 0.8 1.75 ND
Exp. 3 1.4 3 2 6.7 1.9 2 0.9 2.9 1.1
Exp. 4 1.5 1.2 1.8 3.8 1.6 1.7 0.7 1.65 0.9
Exp. 5 0.9 1.5 3.1 2.6 1.7 1.7 0.7 3.2 0.9
Exp. 6 1.3 2.1 4.75 2.8 2.0 2.4 0.65 3.4 0.95
Mean±SD 1.4±0.7 1.9±0.7* 2.9±1.3 4.2±1.5* 2.6±1.4* 1.7±0.4* 0.7±0.15* 2.6±0.7* 1.0±0.1
Abbreviations: DDC, dermal dendritic cell; Exp., experiment; ICOS-L, inducible co-stimulator ligand; LC, Langerhans cell; MFI, mean fluorescence intensity;
ND, not determined; PD-L1, programmed cell death ligand 1.
LCs and CD1c+DDCs were purified after a 2-day migration from epidermis and dermis of the same skin sample. Cells were double-stained with anti-CD1c
and the indicated mAbs and analyzed using flow cytometry. For each antigen, results are expressed as the ratio MFI on LC/MFI on CD1c+DDC. *Significant
difference between MFI from LCs and DDCs at Po0.05.
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phenotype of both cells was comparable to that obtained
after migration from epidermal and dermal sheets, respec-
tively, and, as expected, LCs showed higher allostimulatory
property (not shown). Alternatively, both DC subsets were
incubated for 2 days with CD40L-transfected fibroblasts and
IFN-g, thereby mimicking their interaction with T cells. Upon
activation with CD40L and IFN-g, both CD1cþDDCs and
LCs were able to mature, as evidenced by strong upregulation
of CD54, CD80, and CD86 at the cell surface (see Figures 1b
and 5b for comparison). Indeed, the level of these co-
stimulatory molecules on CD1cþDDCs is at least as high as
that observed on LCs after their migration from epidermis.
However, when compared with CD40L-treated LCs,
CD1cþDDCs remained far less efficient at stimulating
allogeneic T-cell proliferation (Figure 5a). Interestingly, the
2-day treatment with CD40L and IFN-g induced upregulation
of PD-L1 mostly on CD1cþDDCs (see Figures 1b and 5b for
comparison).
DISCUSSION
The skin is continuously exposed to the external environment,
and cutaneous immune responses must be tightly regulated to
both trigger rapid defense against pathogens and prevent
unwanted inflammation and subsequent tissue damage. DCs
are the key sensors of danger and possess the unique ability
to initiate immunogenic or tolerogenic immune responses.
Although recent papers have better characterized the
phenotype of the distinct human epidermal and dermal DC
subsets, the comparative phenotypic and functional charac-
teristics of these cells remain little explored. In this study we
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showed that human LCs are far more efficient than
CD1cþDDCs at inducing naive CD4þ T cells to proliferate
and produce both Th1 and Th2 cytokines. The process might
involve, at least partly, lower expression of CD80 and CD86
and higher expression of PD-L1 on CD1cþDDCs.
The few studies analyzing the comparative phenotypic
and functional properties of human epidermal and dermal
DCs are much debated, probably owing to the methods of
cell recovery, purification, or identification (Morelli et al.,
2005; Klechevsky et al., 2008, Santegoets et al., 2008). Using
DC migration from skin explants, Morelli et al. (2005) first
reported that epidermal and dermal DC populations show
similar mature phenotype and capacity to polarize alloreac-
tive naive CD4þ T cells into Th1 cells. The results are
questionable, however, as these researchers defined LCs as
the CD1aþ and DDCs as the CD1aCD14 migratory cell
populations, whereas both DDCs and LCs are long known to
express CD1a (Meunier et al., 1993; Nestle et al., 1993).
Santegoets et al. (2008) found no difference in activation
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status and allostimulatory properties between migratory
human epidermal and dermal cells. However, they found
dermal cells more efficient than LCs at priming CD8þ T cells.
Because these researchers used crude migratory cell suspen-
sions, the responsible dermal DC remains to be character-
ized. A more recent study has compared the functional
properties of human migratory LCs as well as CD1aþCD14
and CD1aCD14þ dermal DC subsets (Klechevsky et al.,
2008). According to these researchers, the CD14þ DDCs
were specialized in the control of mature B-cell differentia-
tion, whereas LCs were most efficient at priming CD8þ
T cells. Indeed, they found LCs more efficient than
CD1aþCD14 at inducing naive CD8þ T cells to proliferate
and differentiate into potent cytotoxic effectors. Although our
results were restricted to naive CD8þ T-cell proliferation
analysis, they are in line with these findings. Moreover, in
agreement with Klechevsky et al. (2008), we confirmed that
when compared with CD1aþ DDCs, LCs showed lower
levels of co-stimulatory molecules, poorer allostimulatory
function, and lower capacity to induce Th2 cytokine
production by naive CD4þ T cells. However, we consistently
found that LCs were far more potent inducers of both Th1
and Th2 cytokine secretion, whereas Klechevsky et al.
(2008) reported a similar ability of LCs and CD1aþ DDCs
to induce IL-2 and IFN-g production by naive CD4þ T cells.
Notably, we showed that decreasing the APC/T-cell ratio
from 1:10 to 1:100 maintained the secretion of IFN-g and
IL-4 by LC-stimulated T cells, whereas it considerably
reduced the cytokine production by CD1cþDDC- stimulated
T cells.
Using CTLA-4/Ig fusion protein and skin DCs, we
confirmed the predominant role of CD80/CD86/CD28 path-
way in naive T-cell proliferation and differentiation. Hence, it
is likely that the lower expression of the co-stimulatory
molecules on CD1cþ DDCs is involved in their lower
capacity to prime the T cells. Moreover, one of the major
findings in this study was the demonstration of differential
expression of the new molecules of the B7 family—namely,
PD-L1 and ICOS-L—on migratory epidermal LCs and
dermal CD1cþDCs. To our knowledge, these are previously
unreported data. We failed to show the expression of both
molecules on freshly isolated LCs and CD1cþDDCs (not
shown), although one cannot exclude that enzyme treatment
needed for cell recovering had altered the cell surface. In
healthy subjects, PD-L1 was not expressed on blood myeloid
DCs but could be induced upon activation with various
stimuli, including inflammatory cytokines (Fife and Blue-
stone, 2008; Wang et al., 2008). Hence, it is likely that
danger signals induce or increase the expression of these
newly described B7 molecules on skin DCs. However, the
molecular mechanism resulting in distinct expression of PD-
L1, ICOS-L, as well as the other co-stimulatory molecules on
migratory skin DCs is unclear. Indeed, after the 2-day
migration, epidermal supernatant did not contain detectable
levels of IL-1b, tumor necrosis factor-a, or IL-12 inflammatory
cytokines that might have stimulated the LCs (not shown).
Moreover, the distinct phenotypic and functional profile was
maintained after the purified migratory DCs were further
incubated for 2 days with GM-CSF or CD40L and IFN-g. It
was also maintained when newly separated epidermis and
dermis were placed in dermal or epidermal supernatants,
respectively, and the cells recovered 2 days later (data not
shown). Altogether, these data suggest that the distinct
activation state of the migratory skin DCs cannot be related
to the local cytokine environment only but more probably
reflects intrinsic properties of the DC subsets.
Most interestingly, we showed that high PD-L1 expression
on CD1cþ DDCs delivered a co-inhibitory signal to naive
CD4þ T cells by inhibiting both their expansion and
secretion of IFN-g. This is in line with the previous study
showing that PD-L1/Ig fusion protein can attenuate TCR-
mediated T-cell proliferation and cytokine production by
purified CD4þ T cells (Freeman et al., 2000). However, the
inhibitory effect on lymphocyte proliferation can be over-
come by high CD28 co-stimulation. This might explain why
anti-PD-L1 mAb had maximal effect when added to our
relatively immature CD1cþDDCs, whereas the high level of
co-stimulatory molecules on LCs might provide a sufficiently
strong signal to overcome the negative signal provided by
PD-L1 on naive CD4þ T-cell proliferation. In humans, high
expression of PD-L1 on blood myeloid DCs was shown to be
involved in impaired antiviral and antitumor immunity (Fife
and Bluestone, 2008; Seliger et al., 2008; Wang et al., 2008).
Moreover, by limiting T-cell functions, PD-L1 is thought to
control inflammatory responses and tolerance. These results,
together with previous observations (Klechevsky et al., 2008),
therefore raise questions about the role of the CD1cþ DDCs
within human skin. Epidermal LCs and dermal CD14þ DCs
were shown to be essential stimulators of, respectively, the
cellular and humoral arms of immunity (Klechevsky et al.,
2008), and one can wonder whether the CD1cþ dermal DCs
may represent a regulatory DC subset. Indeed, if our in vitro
data have physiological relevance, PD-L1 expression on
dermal CD1cþ DCs might restrict the expansion of effector
T cells, thereby limiting the inflammatory reaction and
controlling skin homeostasis. Another interesting finding
was the high secretion of IL-10 by LC-stimulated CD4þ T
cells when we used a low LC/T-cell ratio. This might suggest
that when the antigen dose is decreasing, LCs themselves are
endowed with regulatory properties. However, how the
different skin DC subsets intervene in the course of immune
response remains to be clarified.
ICOS-L/ICOS interactions have been largely shown to
provide co-stimulatory signals to the T cells, especially
for Th2 cytokine production (Carreno and Collins, 2002;
Greenwald et al., 2005). ICOS-L is expressed on migratory
skin DCs and especially LCs, but we failed to show a
significant role of the ligand in skin DC-induced naive CD4þ
T-cell priming. In a previous report, blockade of ICOS-L
on mature monocyte-derived DCs significantly decreased
both tumor necrosis factor-a and IFN-g production during
primary CD4þ T-cell stimulation (Witsch et al., 2002). The
discrepancy between these and our results probably reflects
the complex balance between the multiple signals delivered
to the T cells, depending on the APCs used. Indeed, the
various molecules that function in concert to positively or
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negatively influence T-cell activation and differentiation
might be important markers in the distinction of DC subsets.
In mice, the role of LCs in generating specific effector
T cells has been questioned in a number of recent
publications. On one hand, it was shown that DDCs but
not LCs can induce protective Th1 response to some
viruses or parasites in mice (Allan et al., 2003; Zhao et al.,
2003; Ritter et al., 2004). The primary function of LCs
has been proposed to be the transport of skin antigen to
draining lymph nodes for transfer to, and presentation
by, lymph node–resident DC populations (Allan et al.,
2006). LC-deficient mice develop enhanced contact hyper-
sensitivity (Kaplan et al., 2005) and, accordingly, LCs were
even thought to induce regulatory rather than effector T-cell
responses. In contrast, murine LCs were shown to initiate
T-cell activation in response to self-antigen rather than
tolerance (Mayerova et al., 2004). Moreover, using bone-
marrow-chimeric mice, Shklovskaya et al. (2008) recently
showed that both migrating LCs and DDCs can induce
primary CD4 T-cell response in vivo, although the cells show
differential activation and migratory behavior. In humans, our
own and previous data (Klechevsky et al., 2008) support a
predominant role of human epidermal LCs in triggering naive
T-cell responses.
In conclusion, in this study we showed that human
migratory LCs and CD1cþDDCs show a distinct phenotypic
pattern and efficiency at priming naive CD4þ T cells, which
adds new knowledge on the biology of these DC subsets. If
these in vitro results are physiologically relevant, they give
further argument that targeting human LCs is particularly
important in the elicitation of immune response. This may be
particularly useful in the development of new therapeutic
strategies using DCs as vaccines.
MATERIALS AND METHODS
Purification of skin DCs after migration from epidermal and
dermal sheets
Human skin was obtained from healthy donors undergoing
abdominal plastic surgery. Samples were obtained after informed
consent and used according to the guidelines of the Declaration of
Helsinki Principles. The study was approved by the institutional
review board of the Universite´ Claude Bernard Lyon 1. Skin was
freed of fatty tissue, and thick slices (3 mm) consisting of epidermis
and dermis were cut using a dermatome. The slices were incubated
in Hanks’ balanced saline solution containing 0.25% dispase II
(Roche, Meylan, France) and 1% gentamycin (Sigma Chemicals,
St Louis, MO) for 1 hour at 37 1C. Epidermis and dermis were
then separated using fine forceps, and washed with Hanks’ balanced
saline solution. Dermal sheets were carefully scratched with
curved forceps to remove residual epidermis. The tissues were
placed in separate Petri dishes containing X-VIVO-15 medium
(Cambrex, Emerainville, France) and 1% gentamycin for 48 hours
at 37 1C in a humidified atmosphere. Epidermal and dermal sheets
were then removed, dried on gauze, and weighed. Roughly, 1 g
of epidermis correlated with about 60 to 80 cm2 epidermis.
Migratory cells were recovered, filtered on sterile gauze, washed
in Hanks’ balanced saline solution, and enumerated. At this step,
enrichment was routinely approximately 40–50% for LCs and
40–60% for DDCs, as assessed using microscopic examination.
LCs were purified using human anti-CD1c-biotin and anti-biotin
microbeads according to the manufacturer’s recommendations
(Miltenyi Biotech, Bergisch Gladbach, Germany). Alternatively,
LCs were purified by two consecutive centrifugations on Lympho-
prep (Flobio SA, Courbevoie, France) and Nycoprep as previously
described (Furio et al., 2009). The two techniques yielded
similar phenotypic and functional results. Dermal migratory cells
were first depleted of CD14þ cells using CD14 microbeads
(Miltenyi Biotech). Routinely, these CD14þ cells represent approxi-
mately 20% of the total migratory cell suspension. The remaining
cells were then purified using human anti-CD1c-biotin and anti-
biotin microbeads. Viability of the purified DC suspensions routinely
exceeded 98%, as assessed by numeration in Trypan blue. Cells were
then used for phenotype analysis and functional T-cell assays.
In some experiments, purified migratory LCs or CD1cþDDCs
(106 cells ml–1) were further incubated for 2 days with or without
poly (I:C) (InvivoGen, San Diego, CA) and cell supernatants were
recovered 2 days later for inflammatory cytokine assay. Alterna-
tively, LCs and CD1cþDDCs (106 cells ml–1) were further incubated
for 2 days with either 200 U ml–1 GM-CSF (Immunotools, Friesoythe,
Germany) or CD40L-transfected fibroblasts and IFN-g (1000 U ml–1)
(generous gifts from the Schering-Plough Research Institute, Kenil-
worth, NJ) and cells were recovered for phenotypic analysis and
assessment of allostimulatory function.
Phenotypic analysis
Migratory LCs and DDCs were pre-incubated with human AB serum
to block Fc receptors and double-stained with a panel of FITC or
phycoerythrin-conjugated mAbs. Cells were incubated for 30 min-
utes at 4 1C and controls were carried out with irrelevant isotype-
matched Igs. The following mAbs were used: anti-HLA-DR
(B8.12.2); anti-CD1a (NA1/34) from Dako (Glostrup, Denmark);
anti-CD1c (AD5- 8E7) from Miltenyi Biotech; anti-CD40 (mAb89),
anti-CD54 (84H10), anti-CD80 (MAB 104), and anti-CD83 (HB15A),
all from Immunotech (Marseille, France); anti-CD86 (2331FUN-1)
from BD Pharmingen (San Diego, CA); anti-PD-L1/B7-H1 (MIH1),
ICOS-L, B7/H2 (MIH12), and B7-DC/PD-L2 (MIH18) mAbs (all
from eBiosciences, San Diego, CA). Intracellular staining with
anti-DC-LAMP mAb (104.G4, Immunotech) was carried out
using the Intrastain Fix/Perm kit (Dako). Analysis of fluorescence
staining was performed with a FACScan flow cytometer (Becton
Dickinson, Le Pont de Claix, France) using the CELLQuest Software
(Becton Dickinson).
Naive CD4þ and CD8þ T-cell purification
Allogeneic T cells were purified from peripheral blood mononuclear
cells by rosetting with sheep red blood cells as previously described
(Kaplan and Clark, 1974). Naive CD4þ T cells were obtained by
negative selection using a naive CD4þ T-cell isolation kit (Miltenyi
Biotec, Auburn, CA). Alternatively, naive CD4þ T cells were
purified from umbilical cord blood mononuclear cells, using
CD4 microbeads (Miltenyi Biotec), and used without altering the
results. In some experiments, both naive CD4þ and CD8þ
T cells were purified from the cord blood using CD4 or CD8
microbeads (Miltenyi Biotec), respectively. The cell populations
were routinely 96–98% pure and contained 0.01–1% CD45ROþ
memory T cells, as assessed using flow cytometry.
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T-cell proliferation assays
Mixed LC– or DDC–lymphocyte reactions were carried out in 96-
well round-bottomed microtiter plates. Purified migratory LCs or
CD1cþDDCs were added in serial twofold dilutions to 105
allogeneic naive CD4þ T cells or, for comparison, to naive CD8þ
T cells. Controls with DCs or T cells alone were included in each
experiment. The culture medium was RPMI-1640 (Gibco Labora-
tories, Grand Island, NY) supplemented with 10% human AB serum
and antibiotics. In some experiments, purified anti-human PD-L1/
B7-H1/CD274 and ICOSL/B7-H2/B7RP-1/CD275 (both from eBios-
ciences, 50 mg ml–1) or recombinant CTLA4/Fc chimera (20 mg ml–1)
with the ability to bind both CD80 and CD86 (R&D Systems, Lille,
France) was added to skin DCs and the plates were kept for
30 minutes at 4 1C before the CD4þT cells were added. Triplicate
cultures were maintained for 5 days at 37 1C in a 5% CO2 humidified
atmosphere. T-cell proliferation was measured by pulsing the cells
with 1mCi of [3H]methylthymidine (25 Ci mmol–1; Amersham
Pharmacia Biotech, Les Ulis, France) for the final 18 hours of
culture. Cells were then harvested, and incorporated thymidine was
quantified in a direct beta counter (Matrix 96; Packard, Downers
Grove, IL). Results were expressed as the mean counts per
minute±SD of triplicate cultures.
Polarization of allogeneic naive CD4þ T cells
Purified migratory LCs or CD1cþDDCs were added to allogeneic
naive CD4þ T cells at a 1:10 or 1:100 APC/T-cell ratio in flat-
bottomed microtiter plates. Culture medium was RPMI-1640 medium
supplemented with 10% human AB serum. In some experiments, DCs
were treated as described above with anti-PD-L1, anti-ICOSL, or
recombinant CTLA4/Fc chimera before the T cells were added. After 6
days, cells were re-stimulated by adding phorbol myristate acetate
(50 ng ml–1; Sigma) and ionomycin (1mg ml–1; Sigma) to the co-culture
wells. Supernatants were collected 24 hours later and stored at80 1C
until Th1/Th2 cytokines were measured. For intracellular cytokine
staining, brefeldin A (10mM, Sigma) was added at 1 hour after
stimulation with phorbol myristate acetate and ionomycin. Cells were
harvested 5 hours later and stained with anti-IFN-g-Alexa Fluor 488,
anti-IL-4-phycoerythrin, or anti-IL-10-phycoerythrin (BD Pharmingen)
after fixation and permeabilization with Intrastain Fix/Perm (Dako). A
mixture of phycoerythrin- and Alexa Fluor 488–conjugated irrelevant
isotype-matched mAbs was used as control.
Cytokine production
The cytokines present in the supernatants of LCs and CD1cþDDCs
stimulated or not with poly (I:C) were measured using the BD CBA
Human Inflammation Kit according to the manufacturer’s recom-
mendations (BD Biosciences, San Jose, CA). The cytokines from skin
DC/CD4þ T-cell co-culture supernatants were measured using the
BD CBA Human Th1/Th2 Cytokine Kit according to the manufac-
turer’s recommendations (BD Biosciences).
Statistical analysis
Results were analyzed for statistical significance using the Wilcoxon
matched-pairs signed-rank test. Only P-values o0.05 were con-
sidered to be significant.
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